Abstract
Microarray-based classifiers and associated signature genes generated from various platforms are abundantly reported in the literature; however, the utility of the classifiers and signature genes in cross-platform prediction applications remains largely uncertain. As part of the MicroArray Quality Control Phase II (MAQC-II) project, we show in this study 80-90% cross-platform prediction consistency using a large toxicogenomics data set by illustrating that: (1) the signature genes of a classifier generated from one platform can be directly applied to another platform to develop a predictive classifier; (2) a classifier developed using data generated from one platform can accurately predict samples that were profiled using a different platform. The results suggest the potential utility of using published signature genes in cross-platform applications and the possible adoption of the published classifiers for a variety of applications. The study reveals an opportunity for possible translation of biomarkers identified using microarrays to clinically validated non-array gene expression assays.
| Original language | English |
|---|---|
| Pages (from-to) | 247-257 |
| Number of pages | 11 |
| Journal | Pharmacogenomics Journal |
| Volume | 10 |
| Issue number | 4 |
| DOIs | |
| State | Published - Aug 2010 |
| Externally published | Yes |
Keywords
- MAQC
- classifier
- cross-platform
- gene signature
- hepatotoxicity
- microarray